Free Trial
NASDAQ:RAPP

Rapport Therapeutics (RAPP) Stock Price, News & Analysis

Rapport Therapeutics logo
$15.38 +1.37 (+9.78%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$16.00 +0.62 (+4.03%)
As of 07/10/2025 06:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Rapport Therapeutics Stock (NASDAQ:RAPP)

Key Stats

Today's Range
$14.01
$15.70
50-Day Range
$8.40
$15.38
52-Week Range
$6.43
$29.74
Volume
260,132 shs
Average Volume
165,737 shs
Market Capitalization
$561.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.00
Consensus Rating
Buy

Company Overview

Rapport Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

RAPP MarketRank™: 

Rapport Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 680th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rapport Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Rapport Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Rapport Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Rapport Therapeutics are expected to grow in the coming year, from ($3.65) to ($3.37) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rapport Therapeutics is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rapport Therapeutics is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Rapport Therapeutics has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Rapport Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    16.26% of the float of Rapport Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Rapport Therapeutics has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Rapport Therapeutics has recently increased by 8.02%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Rapport Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Rapport Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.26% of the float of Rapport Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Rapport Therapeutics has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Rapport Therapeutics has recently increased by 8.02%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Rapport Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Rapport Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for RAPP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Rapport Therapeutics to their MarketBeat watchlist in the last 30 days.
Receive RAPP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RAPP Stock News Headlines

Breakthroughs Backed by Wall Street - This image is an original composition by MarketBeat using licensed and editorial elements. Not for redistribution or reuse.
Analysts Can't Get Enough of These Little-Known Biopharma Stocks (RAPP)
Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
See More Headlines

RAPP Stock Analysis - Frequently Asked Questions

Rapport Therapeutics' stock was trading at $17.74 at the beginning of 2025. Since then, RAPP shares have decreased by 13.3% and is now trading at $15.38.

Rapport Therapeutics, Inc. (NASDAQ:RAPP) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.09.

Rapport Therapeutics (RAPP) raised $136 million in an IPO on Friday, June 7th 2024. The company issued 8,000,000 shares at $17.00 per share.

Shares of RAPP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rapport Therapeutics investors own include Alpha Metallurgical Resources (AMR), Arch Biopartners (ARCH), Global X Copper Miners ETF (COPX), Hims & Hers Health (HIMS), Karuna Therapeutics (KRTX), Longboard Pharmaceuticals (LBPH) and Navios Maritime Partners (NMM).

Company Calendar

Last Earnings
5/08/2025
Today
7/10/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RAPP
Previous Symbol
NASDAQ:RAPP
CIK
2012593
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$28.00
Low Price Target
$28.00
Potential Upside/Downside
+82.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.45)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$78.31 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-25.48%
Return on Assets
-24.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
31.01
Quick Ratio
31.01

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.35 per share
Price / Book
1.84

Miscellaneous

Outstanding Shares
36,500,000
Free Float
N/A
Market Cap
$561.37 million
Optionable
N/A
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:RAPP) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners